J&J is looking to add a hormone-sensitive indication to its prostate cancer therapy, which was originally approved in 2023.

Australians in their 30s and 40s are being diagnosed with cancer at unprecedented rates, with at least 10 types of the ...

J&J has rights to niraparib in prostate cancer, and views the drug as a successor to Zytiga, once a $2.5 billion-a-year ...

Australians aged in their 30s and 40s are experiencing unprecedented and in some cases world-leading rates of 10 different ...

OUR resident specialist and NHS GP, Dr Zoe Williams, shares her expert advice. Today, Dr Zoe helps a reader who is concerned ...

An oncologist has urged men with a certain birth date to stay vigilant for some key cancer symptoms. Men aged 50 and over, ...

An oncologist has urged men with a certain birth date to stay vigilant for some key cancer symptoms. Men aged 50 and over, ...

Prostate cancer is a significant health concern for men worldwide, with increasing diagnoses and fatalities projected. Early ...

Dealing with these decisions isn’t easy while undergoing cancer treatment. But yes, it’s completely understandable to ...

Mack Roach III, MD, discusses the development and evaluation of a multimodal AI algorithm designed to predict prostate cancer outcomes and its performance across racial subgroups.

He identified age as the leading risk factor, noting that cases are rarely seen in men under 40. Genetics and family history ...

Johnson & Johnson has announced the submission of an extension of indication application to the European Medicines Agency (EMA) seeking approval of Akeega (niraparib/abiraterone acetate) with ...